Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment

Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA.
Annals of Neurology (Impact Factor: 11.91). 10/2005; 58(4):623-6. DOI: 10.1002/ana.20558
Source: PubMed

ABSTRACT The 12/15 lipoxygenase (12/15LOX) enzyme is increased in pathologically affected frontal and temporal regions of Alzheimer's disease (AD) brains compared with controls. Herein, we measured 12(S)-HETE and 15(S)-HETE levels, products of 12/15LOX, in cerebrospinal fluid (CSF) of normal individuals, subjects with mild cognitive impairment (MCI) and AD. Compared with controls, there was a significant increase of both metabolites in CSF from AD and MCI, which correlated with lipid peroxidation and tau protein levels. These results suggest that the activation of this enzyme occurs early in the course of AD, before the onset of overt dementia, thereby implicating 12/15LOX-mediated lipid peroxidation in the pathogenesis of AD.

  • Source
    • "In recent years, our laboratory has been interested in the neurobiology of the 12-15LO, an enzyme with pro-inflammatory activity and widely expressed within the central nervous system (Li et al., 1997; Feinmark et al., 2003; Lebeau et al., 2004; Chinnici et al., 2005). Therefore, 12-15LO enzymatic pathway is up-regulated in AD patients compared to their controls (Pratic o et al., 2004; Yao et al., 2005). Previous findings from our group demonstrate "
    [Show abstract] [Hide abstract]
    ABSTRACT: 12/15-Lipoxygenase (12/15LO) is a lipid-peroxidizing enzyme widely expressed in the central nervous system where it has been involved in the neurobiology of Alzheimer disease (AD) because it modulates Amyloid beta (Aβ) and APP processing. However, its biological effect on tau protein is unknown. We investigated the effect of 12/15LO on tau levels and metabolism in vivo and in vitro and the mechanism involved by using genetic and pharmacologic approaches. While no significant differences were observed in the levels of total tau for both groups, compared with controls, Tg2576 mice over-expressing 12/15LO had elevated levels of phosphorylated tau at two specific epitopes, Ser 202/Thr 205 and Ser 396. In vitro and in vivo studies show that 12/15LO modulates tau metabolism specifically via the cdk5 kinase pathway. Associated with these changes were biochemical markers of synaptic pathology. Finally, 12/15-LO-dependent alteration of tau metabolism was independent from an effect on Aβ. Our findings reveal a novel pathway by which 12/15LO modulates endogenous tau metabolism making this protein an appealing pharmacologic target for treatment of AD and related tauopathies. This article is protected by copyright. All rights reserved.
    Aging cell 07/2013; 12(6). DOI:10.1111/acel.12136 · 5.94 Impact Factor
  • Source
    • "Iba-1, a marker for microglia is significantly elevated in AD mice and reduced by J147, while a toxic microglial enzyme, iNOS, is not quite significantly reduced by J147 (Fig. 7B, C). Finally, 5 LOX is a potent reactive oxygen species (ROS) producing and pro-inflammatory enzyme that is increased in AD [74], [75]. This enzyme is also increased in the transgenic mice but levels are dramatically reduced by J147 (Fig. 7D). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently, the major drug discovery paradigm for neurodegenerative diseases is based upon high affinity ligands for single disease-specific targets. For Alzheimer's disease (AD), the focus is the amyloid beta peptide (Aß) that mediates familial Alzheimer's disease pathology. However, given that age is the greatest risk factor for AD, we explored an alternative drug discovery scheme that is based upon efficacy in multiple cell culture models of age-associated pathologies rather than exclusively amyloid metabolism. Using this approach, we identified an exceptionally potent, orally active, neurotrophic molecule that facilitates memory in normal rodents, and prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model.
    PLoS ONE 12/2011; 6(12):e27865. DOI:10.1371/journal.pone.0027865 · 3.23 Impact Factor
  • Source
    • "At the molecular level, familial AD is characterized pathologically by the occurrence of intracellular neurofibrillary tangles rich in tau protein and extracellular plaques containing -amyloid (A ) peptides [123] [124]. These amyloid plaques and neurofibrillary tangles accumulate first in the hippocampal and cortical regions of the brain [125] [126]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Receptors for hormones of the hypothalamic-pituitary-gonadal axis are expressed throughout the brain. Age-related decline in gonadal reproductive hormones cause imbalances of this axis and many hormones in this axis have been functionally linked to neurodegenerative pathophysiology. Gonadotropin-releasing hormone (GnRH) plays a vital role in both central and peripheral reproductive regulation. GnRH has historically been known as a pituitary hormone; however, in the past few years, interest has been raised in GnRH actions at non-pituitary peripheral targets. GnRH ligands and receptors are found throughout the brain where they may act to control multiple higher functions such as learning and memory function and feeding behavior. The actions of GnRH in mammals are mediated by the activation of a unique rhodopsin-like G protein-coupled receptor that does not possess a cytoplasmic carboxyl terminal sequence. Activation of this receptor appears to mediate a wide variety of signaling mechanisms that show diversity in different tissues. Epidemiological support for a role of GnRH in central functions is evidenced by a reduction in neurodegenerative disease after GnRH agonist therapy. It has previously been considered that these effects were not via direct GnRH action in the brain, however recent data has pointed to a direct central action of these ligands outside the pituitary. We have therefore summarized the evidence supporting a central direct role of GnRH ligands and receptors in controlling central nervous physiology and pathophysiology.
    CNS & neurological disorders drug targets 11/2010; 9(5):651-60. DOI:10.2174/187152710793361559 · 2.70 Impact Factor
Show more